AbbVie, Nimble

AbbVie Continues Deal-Making Spree With $200M Nimble Buy
The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and cement its long-term growth prospects following the Phase II failure of emraclidine in schizophrenia and in anticipation of market erosion for Skyrizi and Rinvoq,
AbbVie to acquire Nimble Therapeutics for $200m
The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.
AbbVie Stock Volatile On $200M Deal To Buy Nimble Therapeutics: Retail Still Bearish
Shares of AbbVie Inc. oscillated between gains and losses Friday as the company’s latest acquisition drew mixed reactions from investors. AbbVie announced a $200 million deal to acquire Nimble Therapeutics,
AbbVie To Acquire Nimble Therapeutics For $200 Mln In Cash
Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along
AbbVie Buying Nimble Therapeutics for $200M to Boost Immunology Pipeline
AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics for $200 million in cash in a deal that bolsters the biopharmaceutical company's expansive immunology portfolio. AbbVie on Friday said the deal adds Nimble's lead asset,
AbbVie buying Wisconsin biotech company Nimble Therapeutics for $200 million
AbbVie Inc. said Friday it’s buying Nimble Therapeutics of Madison, Wisconsin, for $200 million. North Chicago-based AbbVie (NYSE: ABBV) said Nimble is working on creating an oral peptide “for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases.
SiliconRepublic32m
AbbVie Ireland appoints Dana Kendall as new GM
As AbbVie Ireland’s new general manager, Dana Kendall will oversee the company’s commercial business in the country.
pharmaphorum5h
AbbVie adds psoriasis med with Nimble takeover
AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...
STAT2d
For a leukemia that keeps returning, AbbVie drug may offer chance for a deep remission
Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to ...
MarketWatch2d
AbbVie Inc. stock underperforms Friday when compared to competitors despite daily gains
Shares of AbbVie Inc. ABBV inched 0.10% higher to $173.37 Friday, on what proved to be an all-around mixed trading session ...
BioPharma Dive2d
AbbVie to acquire Roche spinout Nimble in immune drug deal
The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...
Crain's Chicago Business5d
After one disappointment, AbbVie gets good news out of Cerevel buy
The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
AbbVie Announces Leadership Change with New Appointment
AbbVie ( ) has shared an update. AbbVie announced the retirement of Kevin K. Buckbee from his role as Senior Vice President, Controller, effective March 1, 2025, and the appointme ...
AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...
The Business Journals3d
AbbVie to buy Madison pharmaceutical tech firm for $200 million
Pharmaceutical giant AbbVie Inc. has agreed to acquire Madison's Nimble Therapeutics Inc. for $200 million in cash.